BR9917389A - Formulações tópicas compreendendo agentes de penetração na pele e o uso das mesmas - Google Patents

Formulações tópicas compreendendo agentes de penetração na pele e o uso das mesmas

Info

Publication number
BR9917389A
BR9917389A BR9917389-1A BR9917389A BR9917389A BR 9917389 A BR9917389 A BR 9917389A BR 9917389 A BR9917389 A BR 9917389A BR 9917389 A BR9917389 A BR 9917389A
Authority
BR
Brazil
Prior art keywords
topical formulations
skin penetrating
penetrating agents
compositions
disclosed
Prior art date
Application number
BR9917389-1A
Other languages
English (en)
Other versions
BR9917389B1 (pt
Inventor
Geoffrey Allan
Rajaram Vaidyanathan
Phuong M Vo
George N Manning
Atef A Helmy
Original Assignee
Durham Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Durham Pharmaceuticals Ltd filed Critical Durham Pharmaceuticals Ltd
Publication of BR9917389A publication Critical patent/BR9917389A/pt
Publication of BR9917389B1 publication Critical patent/BR9917389B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

"FORMULAçõES TóPICAS COMPREENDENDO AGENTES DE PENETRAçãO NA PELE E O USO DAS MESMAS". São apresentadas composições tópicas farmacêuticas compreendendo um agente farmacêuticamente ativo como um corticosteróide, um diol, álcool cetilico, monoestearato de glicerila, laurocaprama, álcool esteárico, lauril sulfato de sódio e água. é também apresentado um método para a fabricação das composições e métodos para o tratamento de condições inflamatórias da pele com essas composições.
BRPI9917389-1A 1999-06-25 1999-09-28 formulaÇÕes tàpicas compreendendo agentes de penetraÇço na pele e o uso das mesmas. BR9917389B1 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US14075699P 1999-06-25 1999-06-25
PCT/US1999/022313 WO2001000139A1 (en) 1999-06-25 1999-09-28 Topical formulations comprising skin penetration agents and the use thereof

Publications (2)

Publication Number Publication Date
BR9917389A true BR9917389A (pt) 2002-03-05
BR9917389B1 BR9917389B1 (pt) 2013-04-24

Family

ID=22492675

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI9917389-1A BR9917389B1 (pt) 1999-06-25 1999-09-28 formulaÇÕes tàpicas compreendendo agentes de penetraÇço na pele e o uso das mesmas.

Country Status (15)

Country Link
US (1) US6271219B2 (pt)
EP (1) EP1194109B1 (pt)
JP (1) JP2003506462A (pt)
KR (1) KR100623534B1 (pt)
AT (1) ATE273682T1 (pt)
AU (1) AU769079B2 (pt)
BR (1) BR9917389B1 (pt)
CA (1) CA2376850C (pt)
DE (1) DE69919597T2 (pt)
DK (1) DK1194109T3 (pt)
ES (1) ES2224755T3 (pt)
MX (1) MXPA01013460A (pt)
NZ (1) NZ516765A (pt)
PT (1) PT1194109E (pt)
WO (1) WO2001000139A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL142535A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
EP1551495A4 (en) 2002-10-10 2010-06-02 Yeda Res & Dev BASIC ESTERS OF FAT ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMATORY AGENTS
US20050101605A1 (en) * 2003-11-07 2005-05-12 Ahmed Salah U. Oral liquid formulations of methotrexate
EP1827433B2 (en) 2004-11-29 2015-08-26 Ambria Dermatology AB A composition comprising at least 3 different diols
US7964751B2 (en) 2007-02-26 2011-06-21 Yeda Research And Development Co. Ltd. Enantiomers of amino-phenyl-acetic acid octadec-9-(Z) enyl ester, their salts and their uses
KR100987121B1 (ko) * 2010-08-12 2010-10-12 연세대학교 산학협력단 창문닦기로봇
US11957753B2 (en) 2010-11-22 2024-04-16 Bausch Health Ireland Limited Pharmaceutical formulations containing corticosteroids for topical administration
US8809307B2 (en) 2010-11-22 2014-08-19 Dow Pharmaceutical Sciences, Inc. Pharmaceutical formulations containing corticosteroids for topical administration
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
AR096459A1 (es) * 2013-06-03 2015-12-30 Tolmar Inc Composiciones de corticosteroides y método de fabricación
CN104161721A (zh) * 2014-07-14 2014-11-26 湖北博康医药科技有限公司 一种用于治疗皮肤病的蛇王药剂及其制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4316893A (en) 1975-06-19 1982-02-23 Nelson Research & Development Co. Vehicle composition containing 1-substituted azacycloalkan-2-ones
BE843140A (fr) 1975-06-19 1976-10-18 Aazacycloalcan-2-ones 1-substituees et compositions pharmaceutiques contenant ces composes a titre d'excipients
US4444762A (en) 1980-04-04 1984-04-24 Nelson Research & Development Company Vehicle composition containing 1-substituted azacyclopentan-2-ones
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4537776A (en) 1983-06-21 1985-08-27 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing N-(2-hydroxyethyl) pyrrolidone
US4557934A (en) 1983-06-21 1985-12-10 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing 1-dodecyl-azacycloheptan-2-one
US4886783A (en) 1986-01-31 1989-12-12 Nelson Research & Development Co. Penetration enhancers for transdermal delivery of systemic agents
US5196410A (en) * 1986-10-31 1993-03-23 Pfizer Inc. Transdermal flux enhancing compositions
US4863970A (en) * 1986-11-14 1989-09-05 Theratech, Inc. Penetration enhancement with binary system of oleic acid, oleins, and oleyl alcohol with lower alcohols
JPH0676328B2 (ja) * 1987-04-14 1994-09-28 株式会社大塚製薬工場 ステロイドクリ−ム製剤
DK0437225T3 (da) * 1990-01-10 1994-06-27 Hoffmann La Roche Topiske præparater
JP3207212B2 (ja) * 1991-03-01 2001-09-10 久光製薬株式会社 吸収促進剤およびこれを含有する外用剤
US5607691A (en) * 1992-06-12 1997-03-04 Affymax Technologies N.V. Compositions and methods for enhanced drug delivery
JPH06219947A (ja) * 1993-01-26 1994-08-09 Kinki Univ 経皮投与製剤
US5601839A (en) 1995-04-26 1997-02-11 Theratech, Inc. Triacetin as a penetration enhancer for transdermal delivery of a basic drug
AU718811B2 (en) * 1996-10-30 2000-04-20 Theratech, Inc. Fatty acid esters of glycolic acid and its salts as permeation enhancers

Also Published As

Publication number Publication date
MXPA01013460A (es) 2003-09-04
US20010001790A1 (en) 2001-05-24
AU6060799A (en) 2001-01-31
CA2376850C (en) 2009-11-17
KR100623534B1 (ko) 2006-09-18
ATE273682T1 (de) 2004-09-15
US6271219B2 (en) 2001-08-07
DE69919597D1 (de) 2004-09-23
BR9917389B1 (pt) 2013-04-24
KR20020038595A (ko) 2002-05-23
ES2224755T3 (es) 2005-03-01
WO2001000139A1 (en) 2001-01-04
JP2003506462A (ja) 2003-02-18
PT1194109E (pt) 2004-12-31
DK1194109T3 (da) 2004-10-25
CA2376850A1 (en) 2001-01-04
EP1194109B1 (en) 2004-08-18
EP1194109A4 (en) 2003-01-15
NZ516765A (en) 2003-04-29
AU769079B2 (en) 2004-01-15
EP1194109A1 (en) 2002-04-10
DE69919597T2 (de) 2005-07-14

Similar Documents

Publication Publication Date Title
AR025071A1 (es) Aditivo para mejorar la resistencia al agua de formulaciones cosmeticas o dermatologicas
PT782448E (pt) Formulacoes oticas antibacterianas nao ototoxicas nao sensibilizantes nao irritantes
DE60027463D1 (de) Pharmazeutische zusammensetzungen enthaltend resveratrol und verwendungen davon
ATE370730T1 (de) Pharmazeutische zubereitungen, die chelatbildner/sequestriermittel enthalten und deren dermatologische verwendung
ATE200733T1 (de) Pharmazeutische zubereitungen, die fluoxetin enthalten
BR0109729A (pt) Uso de uma combinação de um agente anti-angiogênico e um agente anti-hipertensivo, kit para uso na produção de um efeito anti-angiogênico e/ou efeito redutor da permeabilidade vascular em um animal de sangue quente, e, método de tratamento de um estado doentio associado com a angiogênese
ZA89233B (en) Topical metronidazole formulations and therapeutic uses thereof
BR0204596A (pt) Composição tópica, e, métodos para melhorar a aparência estética da pele, para intensificar a eficácia terapêutica de uma composição tópica para a pele, unha, lábios e/ou cabelo e para intensificar a produção de um constituinte de célula de planta predeterminada
BR9917389A (pt) Formulações tópicas compreendendo agentes de penetração na pele e o uso das mesmas
SE9704833D0 (sv) New formulation
CO5160321A1 (es) Novedosas composiciones de tipranavir y ritonavir
AU2002231889A1 (en) Halogenated composition, method for preparing same and uses thereof
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
DK0856312T3 (da) Anvendelse af trospiumchlorid til fremstilling af et lægemiddel til behandling af blæresygdomme
Seyger et al. The efficacy of a new topical treatment for psoriasis: Mirak
AR022017A1 (es) Un agente para tratar el trastorno de la funcion de las celulas visuales. el metodo de tratamiento y el uso de dicho agente para la produccion de unacomposicion farmaceutica
BR0009194A (pt) Composição do resorcinol
DE69739482D1 (de) Therapeutische formulierungen, die schlangen- und/oder insektengift enthalten, zur prophylaxe und therapie von neoplasmen
BR9608721A (pt) Composição farmacêutica, e, processo para tratar inflamação
KR20000050667A (ko) 피부 미백 및 피부 질환 치료를 위한 조성물
TH18605A (th) วิธีรักษาโรคจากการติดเชื้อรา

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A, 7A ANUIDADES

B08G Application fees: restoration [chapter 8.7 patent gazette]
B25A Requested transfer of rights approved

Owner name: DURHAM PHARMACEUTICALS ACQUISITION CO. (US)

Free format text: TRANSFERIDO POR INCORPORACAO DE: DURHAM PHARMACEUTICALS LTD.

B25D Requested change of name of applicant approved

Owner name: ECHO THERAPEUTICS, INC. (US)

Free format text: ALTERADO DE: DURHAM PHARMACEUTICALS ACQUISITION CO.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/04/2013, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time
B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)